[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"androgenetic-alopecia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:androgenetic-alopecia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,46,78,107,135,164,192,216,244,272,300,322,349,372,394,418,440,461,486,511,530,552,573],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100474646","1470nm-laser-for-the-treatment-of-androgenetic-alopecia-and-scarring-alopecia-100474646",false,"NCT05460611","1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia","A Pilot Study Evaluating the Safety and Efficacy of a 1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia","Inclusion Criteria:\n\n* Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss\n* Subject must voluntarily sign and date an IRB approved informed consent form\n* Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months\n* Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months\n* Able to read, understand and voluntarily provide written informed consent\n* Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study\n* Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements\n* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period\n\nExclusion Criteria:\n\n* Subject does not have the capacity to consent to the study\n* Subject has other types of alopecia of the scalp like alopecia areata\n* History of intralesional steroid injections to the scalp in the last 12 months\n* Pregnant women\n* Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject\n* Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months\n* Allergy or history of prior reaction to lidocaine\n* History of immunosuppression\u002Fimmune deficiency disorders (including AIDS and HIV infection), and\u002For any history of systemic chemotherapy for prior 12 months\n* History or current use of the following prescription medications:\n\n  i. Immunosuppressive medications\u002Fbiologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months\n* Smoking or vaping in the past 12 months\n* History of uncontrolled hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders\n* History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism",true,"ALL","18 Years","99 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"NA","Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.",[28,29],"Scarring Alopecia","Androgenetic Alopecia",[31,32],"alopecia","laser","RECRUITING","2026-06-09",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":37},"2023-12-07",{"date":41,"type":22},"2028-07",{"name":43,"class":44},"Montefiore Medical Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100640900","phase-1-study-of-epi-001-in-patients-with-androgenetic-alopecia-100640900","NCT07618195","Study of EPI-001 in Patients With Androgenetic Alopecia","Phase I\u002FIIa Study to Evaluate the Safety, Tolerability, and Efficacy of EPI-001 in Patients With Androgenetic Alopecia","Inclusion Criteria:\n\n1. Male or female subjects aged 19 years or older\n2. Subjects diagnosed with androgenetic alopecia\n3. Subjects willing to maintain the same hairstyle, hair length, and hair color during the study period\n4. Subjects willing to refrain from prohibited hair-related products or procedures during the study period\n5. Subjects willing to undergo scalp tattooing and hair trimming for phototrichogram evaluation\n6. Subjects who voluntarily signed written informed consent\n\nExclusion Criteria:\n\n1. Subjects who used prohibited medications or therapies affecting hair growth within the protocol-defined period\n2. Subjects with scalp diseases or hair disorders other than androgenetic alopecia\n3. Subjects with autoimmune diseases affecting the scalp or hair\n4. Subjects with clinically significant cardiovascular, renal, endocrine, infectious, or systemic diseases\n5. Subjects positive for HBV, HCV, HIV, or syphilis screening tests\n6. Subjects with a history of hair transplantation, stem cell therapy, or gene therapy\n7. Subjects with hypersensitivity related to the investigational product or study procedures\n8. Pregnant or breastfeeding women\n9. Subjects who participated in another clinical study within the protocol-defined period\n10. Subjects judged inappropriate for study participation by the investigator","19 Years",{"count":55,"type":22},42,[57,58],"PHASE1","PHASE2","This is a Phase I\u002FIIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia.\n\nIn the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration.\n\nIn the Phase IIa portion, subjects will be randomized in a 2:1 ratio to receive either EPI-001 or placebo. Safety and efficacy will be evaluated through hair count assessment, hair diameter measurement, clinical photography, investigator assessment, expert panel assessment, and subject self-assessment during a follow-up period of up to 48 weeks.",[29],[62,63,64,65,66,67],"Hair Loss","Alopecia","Autologous Cell Therapy","Hair Regeneration","Dermal Papilla Cell","Cell therapy","2026-05-26",{"date":70,"type":37},"2026-06-01",{"date":72,"type":37},"2026-01-12",{"date":74,"type":22},"2029-06-01",{"name":76,"class":77},"Epibiotech","INDUSTRY",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100507556","phase-3-evaluation-of-efficacy-and-safety-of-oral-minoxidil-1-mg-in-female-androgenetic-alopecia-100507556","NCT05888922","Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia","International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia","Inclusion Criteria:\n\n1. Female patients aged 18 years or older, with general good health (i.e., with no history of cardiovascular disorders, or any other clinically significant disease).\n2. Diagnosed with FAGA, based on a discernible decrease in hair density (Sinclair Scale 2-4) in the centroparietal area of the scalp.\n3. Hair color of patient provides sufficient contrast with the scalp and as confirmed by TrichoLab Virtual Tattoo® technology at Screening\u002FVisit 1.\n4. A personally signed and dated informed consent document indicating that the patient, has been informed of all pertinent aspects of the clinical trial.\n5. Negative serum pregnancy test at Visit 1\u002FScreening and negative urine pregnancy test at Visit 2\u002FBaseline for women of child-bearing potential (WOCBP).\n6. WOCBP must either be permanently sterile1 or agree to use a highly effective birth control method (failure rate ˂1% per year when used consistently and correctly) throughout the clinical trial and for at least 2 weeks after last administration of IPs.\n\n   Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2\u002FBaseline and if used as contraceptive and planned to be continued throughout the clinical trial duration.\n7. Patients willing to maintain the same hairstyle (color and hair regimen) throughout the clinical trial. Hair length must remain of sufficient length to not affect determination of hair density and patient should discuss with clinical trial personnel before changing from Visit 2\u002FBaseline.\n8. Patient is willing to maintain the same depilatory habits and intervals regarding facial or body hair before each visit throughout duration of the clinical trial.\n9. Patient is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical trial procedures, including daily e diary recordings by the patient using an own electronic device (e.g., tablet, smartphone, personal computer) and an internet connection during the clinical trial.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or known allergy to minoxidil or to any of the other components of the products.\n2. Pregnancy or pregnancy desire during the clinical trial.\n3. Breastfeeding\u002FNursing women.\n4. Any diagnosed treated or untreated hypertension (or blood pressure values \\>150 mmHg systolic \u002F \\>95 mmHg diastolic) as determined at Visit 1\u002FScreening, and\u002For history\u002Fsigns of known cardiovascular diseases (including but not limited to cardiac ischemia, congestive heart failure, cardiac arrhythmia), and patients with pathologies or punctual situations that might either be caused by or increase the risk of cardiac disorders.\n5. Patients with any dermatological disorders of the scalp in the target region at Visit 1\u002FScreening with the possibility of interfering with the application of the IPs or examination method, such as\n\n   1. Active moderate or severe seborrheic dermatitis under chronic treatment, abrasion, actinic keratosis, or inflammatory disorders, or\n   2. any local infection of the skin\u002Fsubcutaneous tissues of the head within the previous 3 months, or\n   3. any documented history of active atopic dermatitis or psoriasis in the scalp within the previous 6 months.\n   4. any other types of alopecia (e.g., alopecia areata or scarring alopecia) at any time point or diffuse telogen effluvium, trichotillomania, or other pathological hair loss conditions\u002Fdiseases other than AGA in the last 3 months at the discretion of the investigator).\n6. Patients who had hair transplant surgery at any time.\n7. Patients who had hair weaving, or any other hair extension methods within the last 6 months prior to Visit 2\u002FBaseline.\n8. Clinically significant abnormal laboratory values or ECG findings (if applicable) at Visit 1\u002FScreening indicative of physical illness, according to investigator assessment.\n9. Both creatinine and eGFR above upper limit of normal at Visit 1\u002FScreening.\n10. Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases that in the opinion of the investigator may interfere with the aim of the clinical trial.\n11. Patient has used any of the following topical preparations or procedures on the scalp:\n\n    1. Topical scalp treatments for hair growth, including minoxidil within the last 6 months prior to Visit 2\u002FBaseline; or hormone therapy, antiandrogens, or other agents that are known to affect hair growth within 12 weeks prior to Visit 2\u002FBaseline.\n    2. Topical scalp treatments that might have had ancillary effect on hair growth including, but not limited to, corticosteroids, pimecrolimus, and tacrolimus within the last 4 weeks prior to Visit 2\u002FBaseline.\n    3. Topical scalp over the counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Maxilene®, Nioxin®, Foltene®, etc.) or hair health or hair growth products with saw palmetto, copper, etc. within the last 4 weeks prior to Visit 2\u002FBaseline.\n    4. Light or laser treatment or microneedling of scalp within the last 6 months prior to Visit 2\u002FBaseline.\n    5. Platelet rich plasma (PRP) procedure on the scalp within the last 6 months prior to Visit 2\u002FBaseline.\n12. Patient has used the following systemic medications or procedures:\n\n    1. Zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine, benoxaprofen, tamoxifen, phenothiazines, or other vasodilators or antihypertensive agents such as guanethidine and derivatives within the last 12 months prior to Visit 2\u002FBaseline.\n    2. Any 5 alpha reductase medications (i.e., dutasteride, finasteride \\[Propecia®, etc.\\] or similar product\\[s\\]) within the last 12 months prior to Visit 2\u002FBaseline.\n    3. Retinoid therapy within the last 6 months prior to Visit 2\u002FBaseline.\n    4. Beta blockers, anabolic steroids, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2\u002FBaseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable (defined as doses and frequency unchanged for at least 4 weeks prior to Visit 2\u002FBaseline.\n    5. Drugs with antiandrogenic properties, such as flutamide, cimetidine, or ketoconazole within the last 6 months prior to Visit 2\u002FBaseline; bicalutamide within 2 months and spironolactone within 1 month prior to Visit 2\u002FBaseline. Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2\u002FBaseline and if used as contraceptive.\n    6. Minoxidil within the last 6 months prior to Visit 2\u002FBaseline.\n    7. Prostaglandins and derivates within the last 3 months prior to Visit 2\u002FBaseline. Topical and ocular prostaglandins and its derivates are allowed.\n    8. Biotin (\\>5 mg) within the last 4 weeks prior to Visit 2\u002FBaseline.\n    9. Previous radiation of the scalp and treatment with chemotherapy\u002Fsystemic cytotoxic agents at any timepoint.\n13. Participation in the evaluation of any investigational drugs within 30 days or 5 half lives (whichever is longer) prior to Visit 2\u002FBaseline, calculated from the first day of the month following the last visit of the previous clinical trial.\n14. History of drug and alcohol dependency.\n15. In the opinion of the investigator the patient should not participate in the clinical trial, e.g., due to probable non compliance or inability to understand the clinical trial and give adequately informed consent.\n16. Close affiliation with the investigator (e.g., a close relative) or persons working at the clinical trial centers or patient is an employee of sponsor.\n17. Patient is institutionalized because of legal or regulatory order.","FEMALE",{"count":87,"type":22},520,[89],"PHASE3","The goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss.\n\nThe main questions to answer are to know about that minoxidil 1mg is as effective as minoxidil 2% topical solution (comparator product) and is more effective than placebo; and to ensure treatment with oral minoxidil is safe.\n\nParticipants will be assigned randomly to receive one of the following treatment combinations:\n\n* the test product (oral minoxidil 1 mg, once\u002Fday) and the vehicle solution (vehicle means it looks like the comparator product, but it does not contain an active ingredient, 2 times\u002Fday), or\n* the placebo tablet (placebo means it looks like the test product, but it does not contain an active ingredient, once\u002Fday) and the comparator product (2% minoxidil solution, 2 times\u002Fday), or\n* the placebo tablet (once\u002Fday) and the vehicle solution (2 times\u002Fday).\n\nThe clinical trial will take up to 36 weeks. During this time, patients will come to the clinical trial centre for 5 times for examinations and will be called by phone twice. At the visits, the following examinations will be performed: photos of the hair will be taken to determine hair density, assessment of changes in scalp hair growth, measurement of blood pressure, pulse, and body temperature, a physical examination, blood withdrawal to determine any abnormalities in the blood, urine sampling and analysis, performance of ECG, and evaluation of hypertrichosis (i.e., excessive hair growth over the body). Furthermore, patients will be asked daily whether they had experienced any side effects or took any new medications (or changed the dose of a known medication) or underwent any medical procedure. Also, women of childbearing potential must undergo pregnancy tests in blood and urine.",[29,92],"Female Pattern Baldness",[94,92,95,96],"Androgenetic alopecia","FAGA","Minoxidil","2026-05-08",{"date":99,"type":37},"2026-05-12",{"date":101,"type":37},"2024-10-17",{"date":103,"type":22},"2026-11",{"name":105,"class":77},"Industrial Farmacéutica Cantabria, S.A.",13,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":16,"sex":114,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":45},"100636234","jak2-expression-in-androgenetic-alopecia-before-and-after-topical-minoxidil-100636234","NCT07563036","JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil","Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy.","Inclusion Criteria:\n\n* Male adults aged 18 to 50 years with androgenetic alopecia.\n* Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.\n* Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Other types of hair loss, including inflammatory or scarring alopecia.\n* Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.\n* Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.\n* History of severe systemic disease, including renal, cardiovascular, or hepatic disease.\n* Chemotherapy during the last 5 years.\n* Bleeding disorders.","MALE","50 Years",{"count":117,"type":22},25,[25],"Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.",[29,121],"Androgenic Alopecia",[121,123,124,125],"Janus Kinase 2","JAK2","minoxidil","2026-04-25",{"date":128,"type":37},"2026-05-01",{"date":130,"type":37},"2026-02-01",{"date":132,"type":22},"2027-01-01",{"name":134,"class":44},"Kasr El Aini Hospital",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100632796","phase-4-the-effect-of-nanofat-injection-on-androgenetic-alopecia-100632796","NCT07518342","The Effect of Nanofat Injection on Androgenetic Alopecia","Efficacy and Safety of Nanofat Injection vs Either PRP Injection or Topical Minoxidil 5% in Female and Male Pattern Androgenetic Alopecia","Inclusion criteria:\n\n* Adults (ages 18-50).\n* A clinical diagnosis of androgenetic alopecia confirmed by dermoscopy of both males and females.\n* No previous topical treatment used in the past 3 months.\n\nExclusion criteria:\n\n* Alopecia totalis and alopecia universalis.\n* Cicatricial alopecia.\n* Other causes of hair loss such as immunological disease.\n* Skin disease in the affected area.\n* Hypersensitivity or allergy to any of the treatment products used.\n* Patients using treatment (topical or systemic) for androgenetic alopecia in the last 3 months.\n* Pregnant and lactating females.\n* Patients with a history of hypertrophic scars or keloid formation.\n* Patients with active infection at the site of the lesion.\n* Skin disease in the affected area.\n* Hamilton norwood scale stage 6 and 7\n* Ludwig Scale stage 3",{"count":143,"type":22},60,[145],"PHASE4","Androgenetic alopecia is a condition that bothers a lot of people. The disadvantage of the FDA approved topical minoxidil is that the patient needs to be compliant every day for extended periods of time. This is the main reason why this study is being conducted, to see if a single nanofat injection is superior to applying either topical Minoxidil or PRP",[29,148],"Androgenetic Alopecia (AGA)",[29,63,150,151,152,96,153],"PRP","nanofat","nanofat injection","Topical minoxidil","NOT_YET_RECRUITING","2026-04-08",{"date":157,"type":37},"2026-04-13",{"date":159,"type":22},"2026-04",{"date":161,"type":22},"2028-12",{"name":163,"class":44},"Assiut University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":114,"minAge":18,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100633691","phase-3-phase-3-study-to-evaluate-the-efficacy-and-safety-of-oral-minoxidil-n1087-in-men-with-androgenetic-alopecia-100633691","NCT07529977","Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.","A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Male Participants With Androgenetic Alopecia.","MINORA-MEN","Inclusion Criteria:\n\n* Male participants aged 18 to 60 years at the time of signing the informed consent form.\n* Clinical diagnosis of androgenetic alopecia classified as stages 3V, 4, or 5 according to the Norwood-Hamilton scale, based on the investigator's clinical assessment.\n* No specific treatment for androgenetic alopecia in the last 6 months, or history of specific treatment for androgenetic alopecia for up to 30 days within the last 6 months.\n* Willingness to comply with all study procedures and assessments, including permanent scalp tattooing and shaving of the target area.\n* Willingness to maintain hairstyle, hair length, and hair color throughout the study.\n* Willingness to maintain consistent use of hair products and general hair care routine throughout the study.\n* Global scalp photograph obtained at Screening Visit validated centrally prior to randomization.\n\nExclusion Criteria:\n\n* Presence of other causes of alopecia, such as alopecia areata, scarring alopecia, traction alopecia, nutritional deficiency-related alopecia, monilethrix, trichotillomania, trichodystrophy, or chemotherapy-induced alopecia.\n* History of telogen effluvium within the last 6 months.\n* Presence of other dermatological conditions affecting the scalp, such as seborrheic dermatitis, psoriasis, eczema, or fungal infections.\n* Clinically relevant uncontrolled endocrine disorders that may affect the hair cycle.\n* Uncontrolled thyroid disease.\n* History of autoimmune diseases or collagen vascular diseases.\n* Use of testosterone, its analogues, anabolic steroids, or other systemic androgen therapies within the last 6 months.\n* History of organ transplantation.\n* Physical treatments for hair loss within the last 6 months, such as microneedling, laser therapy, or platelet-rich plasma.\n* History of hair transplantation or use of hairpieces.\n* Severe uncontrolled systemic arterial hypertension or hypotension.\n* History of significant cardiovascular disease, including myocardial infarction, unstable angina, or congestive heart failure (NYHA class III or IV).\n* History or suspicion of pulmonary hypertension associated with mitral stenosis or pheochromocytoma.\n* History of peripheral edema, lymphedema, ascites, or pericardial effusion.\n* Resting tachycardia (heart rate ≥100 bpm).\n* Moderate to severe renal, hepatic, or cardiovascular disease.\n* History of malignancy within the last 5 years, except for successfully treated non-metastatic basal or squamous cell carcinoma of the skin.\n* Current use of potent vasodilators or other prohibited medications.\n* Known allergy or hypersensitivity to minoxidil or any component of the formulation.\n* Hairstyles that may interfere with study assessments, such as permanent braids or dreadlocks.\n* Participants with reproductive potential whose partner does not agree to use effective contraception during the study.\n* Participation in another clinical trial within the last 12 months.\n* Clinically significant laboratory abnormalities at randomization, including HbA1c ≥8%, estimated glomerular filtration rate \\\u003C45 mL\u002Fmin, elevated liver enzymes (\\>2× ULN), abnormal thyroid-stimulating hormone levels, clinically significant ECG abnormalities, hemoglobin \\\u003C13 g\u002FdL, or hematocrit \\\u003C39%.","60 Years",{"count":174,"type":22},372,[89],"This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).\n\nThe study will include male participants aged 18 to 60 years who have a clinical diagnosis of androgenetic alopecia classified as stages 3V, 4, or 5 on the Norwood-Hamilton scale. Participants will be randomly assigned, in a 2:1 ratio, to receive either N1087 or placebo. Neither the participants nor the study team will know which treatment each participant receives.\n\nThe study treatment will be taken orally once daily for a total of 24 weeks. During the first 8 weeks, the dose will be gradually increased (titration period) up to a maximum tolerated dose, not exceeding 5 mg. Participants will then continue treatment at the maximum tolerated dose for the remaining 16 weeks.\n\nThe main purpose of the study is to assess whether oral minoxidil improves hair growth. The primary outcome measure is the change from baseline in the density of non-vellus hairs in a defined target area of the scalp (vertex) after 24 weeks of treatment, measured using digital phototrichogram analysis.\n\nSecondary objectives include evaluating changes in hair density at earlier time points, hair thickness, the proportion of terminal hairs, clinical improvement assessed by the investigator, quality of life related to hair loss, and participant satisfaction with treatment.\n\nThe safety and tolerability of oral minoxidil will also be evaluated by monitoring adverse events, vital signs, and events of special interest throughout the study. An independent Data and Safety Monitoring Committee will oversee participant safety during the trial.\n\nThis is a multicenter study conducted in Brazil, with approximately 372 participants expected to be enrolled.",[29,148],[94,179,180,181,182,183],"Male pattern hair loss","N1087","Hair growth","Phototrichogram","Phase 3 clinical trial",{"date":185,"type":37},"2026-04-14",{"date":187,"type":22},"2027-01-31",{"date":189,"type":22},"2028-10-30",{"name":191,"class":77},"Eurofarma Laboratorios S.A.",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":207,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100565951","phase-2-clinical-study-of-da-001-as-a-treatment-for-hair-shedding-reduction-and-hair-re-growth-100565951","NCT06648850","Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with telogen effluvium\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-001\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits",{"count":199,"type":22},1120,[58,89],"The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth",[203,204,205,206,29,148],"Telogen Effluvium","Female Pattern Hair Loss","Female Pattern Hair Loss, Androgenic Alopecia","Male Pattern Baldness",[208,209],"Hair Shedding","hair growth",{"date":157,"type":37},{"date":128,"type":22},{"date":213,"type":22},"2027-04-26",{"name":215,"class":77},"Applied Biology, Inc.",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":16,"sex":114,"minAge":53,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":242,"locationsCount":45},"100630642","phase-1-assessment-of-dutasteride-topical-solution-in-male-androgenetic-alopecia-100630642","NCT07490327","Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia","A Randomized, Open-label, Single and Multiple-dose, Parallel-design Phase 1\u002F2a Clinical Trial to Evaluate the Pharmacokinetics\u002FPharmacodynamics and Safety of AD-303A and Oral Administration of AD-3031 in Male Androgenetic Alopecia Patients","Inclusion Criteria:\n\n* Male participants aged 19 to 55 years.\n* Clinical diagnosis of androgenetic alopecia.\n* Healthy as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests.\n* Willing and able to comply with all study procedures and visit schedules.\n\nExclusion Criteria:\n\n* History or presence of dermatologic conditions affecting the scalp other than androgenetic alopecia.\n* Prior hair transplantation or scalp surgery that may affect evaluation of hair growth.\n* Use of medications known to affect hair growth (e.g., finasteride, dutasteride, minoxidil) within 6 months prior to screening.","55 Years",{"count":225,"type":22},30,[57,58],"This is a randomized, open-label phase 1\u002F2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.",[29],[230,29,231,232,233,234,235],"AD-303A \u002F AD-3031","Dutasteride","Topical","5-Alpha Reductase Inhibitor","Pharmacokinetics","Safety","2026-03-19",{"date":238,"type":37},"2026-03-24",{"date":159,"type":22},{"date":241,"type":22},"2026-12",{"name":243,"class":77},"Moogene Medi Co., Ltd",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":16,"sex":17,"minAge":250,"maxAge":115,"enrollmentInfo":251,"targetDuration":4,"studyType":253,"phases":4,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":268,"leadSponsor":270,"locationsCount":45},"100615569","harnessing-artificial-intelligence-for-diagnosing-androgenetic-alopecia-a-training-and-validation-study-100615569","NCT07294313","Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study","for the patient group:\n\nInclusion criteria:\n\n* Patients with male or female pattern hair loss diagnosed clinically or suspected clinically and confirmed trichoscopically\n* Age of disease onset 12-50 years old\n* Both genders\n* Any grade of androgenetic alopecia\n* Any duration of androgenetic alopecia\n* Any skin type\n\nExclusion criteria by clinical and trichoscopic examination:\n\n* Patients with patchy hair loss or Telogen effluvium only.\n* Patients with cicatricial alopecia or diffuse alopecia areata\n* Patients with inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution)\n* Lack of patient cooperation.\n\nfor the control group: apparently healthy participants not suffering from the following: AGA, patchy hair loss, cicatricial alopecia, diffuse alopecia areata, inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution).","12 Years",{"count":252,"type":22},400,"OBSERVATIONAL","The aim of this study is to develop and validate deep learning models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image by handheld dermoscopy and administrative data (age and sex).",[29],[29,257,258,259,260,261,262,263,264],"deep learning","Artificial Intelligence","Convoluted neural network","trichoscopy","female pattern hair loss","male pattern hair loss","handheld dermoscope","hair count",{"date":266,"type":37},"2026-03-20",{"date":126,"type":22},{"date":269,"type":22},"2026-11-25",{"name":271,"class":44},"Cairo University",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100630034","phase-1-xvie-to-treat-androgenetic-alopecia-aga-100630034","NCT07482423","XVIE to Treat Androgenetic Alopecia (AGA)","A Phase I\u002FII Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of XVIE Injected Intradermally in Patients With Androgenetic Alopecia","Inclusion Criteria:\n\n* Male or female, aged 18 to 70 years (inclusive) at the time of informed consent\n* Able to understand and voluntarily provide written informed consent\n* Willing and able to comply with study procedures, including all scheduled visits and assessments\n* In good general health as determined by the Investigator based on medical history and screening assessments\n* Clinical diagnosis of androgenetic alopecia (AGA) with documented hair loss for at least 6 months prior to screening\n* Stable pattern of hair loss (no rapid progression) for at least 6 months prior to screening\n* Male subjects: Norwood-Hamilton Classification Stage III, IIIa, IIIv, IV, or IVa\n* Female subjects: Ludwig Classification Stage I or II\n* Normal thyroid function (TSH within normal limits) at screening, or stable on thyroid replacement therapy for at least 6 months\n* Ferritin level within normal limits at screening, or documented adequate iron stores\n* No clinically significant abnormalities on CBC with differential or comprehensive metabolic panel (CMP) at screening outside protocol-defined eligibility thresholds\n* Female subjects of childbearing potential must have a negative urine pregnancy test at screening and agree to use an effective method of contraception throughout the study and for 30 days after the last treatment\n* Female subjects who are postmenopausal (no menses for at least 12 months) or surgically sterile are not required to use contraception\n\nExclusion Criteria:\n\n* Use of topical or oral minoxidil within 3 months prior to screening\n* Use of oral finasteride or dutasteride within 6 months prior to screening\n* Use of topical finasteride within 3 months prior to screening\n* Platelet-rich plasma (PRP), exosome, or other regenerative scalp injections within 6 months prior to screening\n* Hair transplant surgery within 12 months prior to screening\n* Low-level laser therapy (LLLT) or other light-based hair treatments within 3 months prior to screening\n* Scalp microneedling within 3 months prior to screening\n* Use of drugs with anti-androgenic properties (e.g., spironolactone, cyproterone acetate, flutamide) within 6 months prior to screening\n* Systemic corticosteroids within 2 weeks prior to screening, or corticosteroid scalp injections within 1 month prior to screening\n* Chronic daily NSAID use (defined as daily use for 14 or more consecutive days), other than low-dose aspirin (81 mg\u002Fday or less) for cardiovascular prophylaxis\n* Diagnosis or history of alopecia areata, cicatricial (scarring) alopecia, telogen effluvium, traction alopecia, or other non-AGA hair loss conditions\n* Norwood-Hamilton Stage V, VI, or VII (male subjects); Ludwig Stage III (female subjects)\n* Active or history of malignancy within 5 years prior to screening, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix\n* Known or suspected autoimmune disease (e.g., lupus, rheumatoid arthritis, psoriasis with scalp involvement)\n* Known or newly identified immunodeficiency or immunocompromised state, including HIV infection identified at screening\n* Positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) at screening\n* Platelet count less than 100,000\u002FµL, bleeding disorder, or hemoglobin less than 10 g\u002FdL at screening\n* Current use of anticoagulant therapy (e.g., warfarin, heparin, direct oral anticoagulants), P2Y12 receptor inhibitors (e.g., clopidogrel, prasugrel, ticagrelor), phosphodiesterase inhibitor antiplatelet agents (e.g., cilostazol, dipyridamole), or dual antiplatelet therapy\n* Uncontrolled thyroid disease or thyroid dysfunction not adequately managed on stable therapy\n* Uncontrolled diabetes (HbA1c greater than 9%) or other significant metabolic disorder\n* Active scalp infection, inflammation, or dermatological condition in the treatment area\n* Open wounds, abrasions, or abnormalities on the scalp in the intended treatment area\n* History of keloid formation or propensity for keloids\n* Hair weaving or use of hair pieces that cannot be removed for study assessments\n* Known hypersensitivity or allergy to any component of XVIE or human-derived biological products\n* Known allergy to lidocaine or other local anesthetics\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the study period\n* Positive urine pregnancy test at screening or Day 0\n* Participation in another interventional clinical trial within 30 days prior to screening or concurrent participation in another clinical study\n* History of drug or alcohol abuse within 12 months prior to screening\n* Use of systemic immunosuppressive therapy within 5 half-lives or 30 days prior to screening, whichever is longer, including biologic agents, conventional DMARDs, JAK inhibitors, and calcineurin inhibitors\n* Use of topical JAK inhibitors applied to the scalp within 30 days prior to screening\n* Any condition that, in the Investigator's judgment, would make the subject unsuitable for study participation","70 Years",{"count":225,"type":22},[57,58],"This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss). XVIE contains growth factors and extracellular vesicles that may stimulate hair follicle activity. Thirty participants will be randomly assigned to receive either XVIE or a saline placebo injected into the scalp in two treatment sessions, 90 days apart. Neither participants nor study staff will know which treatment is being given. Participants will be followed for 6 months. The main goal is to evaluate safety. A secondary goal is to assess whether hair count, density, or coverage improves.",[29],[94,285,286,287,288,289,290,291],"Pattern hair loss","Extracellular vesicles","Human amniotic fluid","Intradermal injection","Hair regrowth","Decellularized biological product","XVIE","2026-03-16",{"date":236,"type":37},{"date":128,"type":22},{"date":296,"type":22},"2027-05-01",{"name":298,"class":77},"Restore Biologics Holdings, Inc. dba Xtressé",2,{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":45},"100599164","phase-3-efficacy-and-safety-of-5-minoxidil-foam-in-female-androgenetic-alopecia-100599164","NCT07080931","Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia","Inclusion Criteria:\n\n* Voluntarily participate in the study and be able to provide a written Informed Consent Form (ICF);\n* Female aged ≥ 18 years;\n* Investigator-diagnosed androgenetic alopecia;\n* Hair loss severity graded D3 to D6 on the Savin scale;\n* Willingness to maintain identical hairstyle, hair color, and hair length at each follow-up visit;\n* No pregnancy plans during the study and for 3 months post-last dose, with commitment to highly effective contraception. Women of childbearing potential must have negative serum pregnancy test ≤7 days prior to first investigational product administration\n\nExclusion Criteria:\n\n* Trial participants with known hypersensitivity to minoxidil or any excipient of the investigational product.\n* Trial participants with known hair loss disorders other than androgenetic alopecia (AGA)\n* Trial participants with any scalp disorder at screening that may interfere with efficacy evaluation, as determined by the investigator.\n* Lactating women\n* Trial participants with history of hypotension or uncontrolled hypertension\n* Trial participants with clinically significant abnormal laboratory findings at screening that may compromise efficacy and safety assessments, as determined by the investigator.\n* Trial participants with clinically significant ECG abnormalities at screening\n* Trial participants with history of malignancy prior to screening.\n* Trial participants known to have conditions or disorders that may affect hair growth or compromise study results.\n* Trial participants with history of using systemically administered therapeutic drugs prior to screening that may interfere with efficacy evaluation, etc.\n* Trial participants with history of topical minoxidil application to alopecia-affected areas prior to screening.\n* Trial participants with no response to prior minoxidil treatment for alopecia\n* Trial participants with history of 5α-reductase inhibitor use prior to screening.\n* Trial participants with history of spironolactone or cyproterone treatment prior to screening.\n* Trial participants with history of autologous platelet-rich plasma (PRP) administration prior to screening.\n* Trial participants with history of chemotherapy, cytotoxic agents, scalp radiation, and\u002For low-level laser therapy (LLLT) or surgical scalp procedures for FAGA prior to screening.\n* Trial participants with history of using medical shampoos or solutions containing ingredients or other components that may interfere with efficacy evaluation prior to screening.\n* Trial participants planning hair transplantation during the study period, or using hair weaving, non-breathable wigs, or hair bonding during treatment.\n* Trial participants in other interventional clinical trials within 3 months before screening (excluding non-interventional studies and screen failures) , or planned concurrent clinical trial enrollment.\n* Trial participants with history of major surgery within 3 months before screening or planning major surgery during the study period.\n* Trial participants deemed by the investigator to have other conditions that may compromise compliance or render them unsuitable for the study.",{"count":308,"type":22},294,[89],"The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.",[29],[29],"2026-03-03",{"date":315,"type":37},"2026-03-05",{"date":317,"type":37},"2025-02-24",{"date":319,"type":22},"2027-12",{"name":321,"class":77},"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":329,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":45},"100625947","phase-1-secretome-vs-prp-injections-for-hair-density-and-growth-in-androgenetic-alopecia-patients-100625947","NCT07429253","Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients","Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital","Inclusion Criteria:\n\n* Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.\n* Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.\n* Female patients who are not currently pregnant or breastfeeding.\n* Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.\n* Patients with no known allergies to secretome components and\u002For materials used in the platelet-rich plasma (PRP) preparation process.\n* Patients who are proficient in Indonesian and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Participants who are unable to speak or understand Indonesian and\u002For are unwilling to provide written informed consent.\n* Patients presenting with types of hair loss other than androgenetic alopecia.\n* Patients currently undergoing therapy with 5-alpha reductase inhibitors.\n* Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.\n* Patients with active infections and\u002For active dermatitis on the scalp.\n* Patients with a known history of allergy to secretome components and\u002For materials used in the platelet-rich plasma (PRP) preparation process.\n* History of hypertrophic scarring or blood clotting (coagulation) disorders.\n* Patients unable to complete the research procedures in their entirety.","25 Years","59 Years",{"count":332,"type":22},40,[57,58],"This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.",[29],[337,338,29,339],"Secretome","Platelet-Rich Plasma","Trichoscopy","2026-02-17",{"date":342,"type":37},"2026-02-24",{"date":344,"type":37},"2026-01-09",{"date":346,"type":22},"2026-09-30",{"name":348,"class":77},"PT. Prodia Stem Cell Indonesia",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":114,"minAge":18,"maxAge":172,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":45},"100408097","phase-3-efficacy-and-safety-of-finlndia-hair-lotion-association-on-androgenetic-alopecia-100408097","NCT04594018","Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia","National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia.","Inclusion Criteria:\n\n* Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;\n* Men aged 18 years or over and less than or equal to 60 years with a diagnosis of Androgenetic Alopecia grades IIIv to IV in the modified Norwood-Hamilton classification, who have been using minoxidil 5% for at least 3 months and willing to maintain the same style, approximate length and hair color throughout the test.\n\nExclusion Criteria:\n\n* Known hypersensitivity to the formula components used during the clinical trial;\n* History of alcohol and\u002For substance abuse within 2 years;\n* Participants with other concomitant dermatological diseases on the scalp, except for mild seborrhoea dermatitis;\n* Participants with a history of surgical treatment for hair loss or shaved scalp;\n* Participants who used shampoo or topical solution containing ketoconazole, tar, selenium, threonine or steroids in the last 2 weeks;\n* Participants who used 5α reductase inhibitors, such as finasteride and dutasteride, in the last 12 months;\n* Participants using testosterone replacement therapy (TRT) or using testosterone-containing gel;\n* Participants who used micro-infusion of medications on the skin (MMP), microneedling or intradermotherapy on the scalp in the last 3 months;\n* Participants who have undergone radiation treatment for the scalp or chemotherapy in the past year;\n* Participants with diseases that can affect hair growth;\n* Participants with a current medical history of cancer and \u002F or cancer treatment in the last 5 years;",{"count":357,"type":22},190,[89],"The purpose of this study is to evaluate the efficacy of Finlândia hair lotion association in the treatment of androgenetic alopecia.",[29],[362],"androgenetic alopecia","2025-12-01",{"date":365,"type":37},"2025-12-08",{"date":367,"type":37},"2023-02-02",{"date":369,"type":22},"2027-09",{"name":371,"class":77},"EMS",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":114,"minAge":18,"maxAge":115,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":45},"100612040","a-split-scalp-study-evaluating-the-efficacy-and-safety-of-fractional-laser-therapy-with-and-without-exosomes-in-the-treatment-of-androgenetic-alopecia-100612040","NCT07248410","A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia","Inclusion Criteria:\n\n1. Male pattern baldness diagnosed according to the Norwood-Hamilton classification III-V\n2. Males aged 18 to 50 years\n3. Willing to provide written informed consent and possessing the ability to read, write, speak, and understand\n4. Able to follow the study's treatment guidelines\n\nExclusion Criteria:\n\n1. Those who have taken oral Finasteride, Dutasteride, or Minoxidil within 6 months prior to the start of the trial.\n2. Those who have used any topical or systemic medications that may affect hair growth within 6 months prior to the start of the trial.\n3. Those who have received phototherapy, laser therapy, exosome therapy, or hair regrowth injections (such as minimally invasive procedures) within 6 months prior to the start of the trial.\n4. Those with a history of hair transplant surgery.\n5. Those suffering from other systemic or scalp diseases that may affect hair growth (e.g., iron deficiency anemia, immune disorders, thyroid diseases, and syphilis).\n6. Those with a history of severe inflammation, keloids, malignant tumors, or poor wound healing at the treatment site.\n7. Those with other diseases that make them unsuitable for fractional laser treatment.\n8. Those with a history of malignant tumors or currently undergoing treatment.\n9. Participants must not undergo any cosmetic procedures that may affect scalp condition or hair growth throughout the entire trial period, including hair dyeing, perming, bleaching, scalp exfoliation, deep scalp cleansing, or any other actions that may irritate or damage the scalp.",{"count":225,"type":22},[25],"This trial aims to evaluate the efficacy, safety, and tolerability of fractional laser combined with topical exosome for hair regrowth in patients with androgenetic alopecia.\n\nThis study is expected to recruit 30 participants. The experimental group will receive fractional laser treatment combined with human umbilical cord mesenchymal stem cell exosome solution; the control group will receive fractional laser treatment combined with a placebo. Participants will receive three fractional laser treatments and will be followed up for 6 months. At each follow-up visit, hair density, diameter, vellus hair to terminal hair ratio, and adverse reactions will be assessed using trichotomy; a global photographic assessment will be performed using standardized imaging equipment.",[29],[29,383,125,384],"exosome","fractional laser","2025-11-18",{"date":387,"type":37},"2025-11-25",{"date":389,"type":22},"2025-11-24",{"date":391,"type":22},"2027-10-31",{"name":393,"class":44},"Chang Gung Memorial Hospital",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":409,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":417},"100604169","phase-3-safety-and-efficacy-of-vdphl01-in-females-with-androgenetic-alopecia-aga-100604169","NCT07146022","Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia","Inclusion Criteria:\n\n* Subject is a female aged 18-65 years old;\n* Subject has a clinical diagnosis of mild to moderate AGA;\n* Subject is in good general health and has adequate renal and hepatic function;\n* Subject is willing to maintain at least 1\u002F4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;\n* Subject is willing and able to administer the test article as directed and can read, understand, and complete the required questionnaires in English;\n* Subject is willing and able to swallow study drug whole;\n* Subject agrees to have a micro dot tattoo placed on their scalp;\n* Subject agrees to have this area photographed at study visits as indicated in the protocol.\n\nExclusion Criteria:\n\n* Subject has uncontrolled blood pressure or orthostatic hypotension;\n* Subject has symptoms or history of certain heart or thyroid conditions;\n* Subject has a history of or active hair loss due to conditions\u002Fdiseases other than AGA;\n* Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists;\n* Subject has been diagnosed with COVID-19 within 16 weeks of baseline;\n* Subject has had previous radiation of the scalp;\n* Use of any of the following treatments within the indicated washout period before screening:\n\n  * Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening\n  * Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening\n  * Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening\n  * Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening\n  * Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, platelet rich plasma within 6 months prior to screening\n  * Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening\n  * Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study;\n  * Subject has any other condition that, in the investigator's opinion, interfere with the study","65 Years",{"count":403,"type":22},552,[89],"This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA).\n\nAGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.\n\nThis multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).",[148,29,407,408,62],"AGA","Female Androgenetic Alopecia",[29,407,62],{"date":389,"type":37},{"date":412,"type":37},"2025-07-25",{"date":414,"type":22},"2028-01",{"name":416,"class":77},"Veradermics, Inc.",71,{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":114,"minAge":18,"maxAge":425,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":431,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":45},"100601599","phase-1-evaluation-of-exosomes-injection-in-treatment-of-male-androgenetic-alopecia-clinical-and-immunohistochemical-study-100601599","NCT07112586","Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study","Evaluation of Intradermal Exosome Injection in Treatment of Male Androgenetic Alopecia: A Clinical and Immunohistochemical Study","Inclusion Criteria:\n\n\\- Androgenetic Alopecia Grades 1-4\n\nExclusion Criteria:\n\n* blood diseases Receiving other treatments History of malignancy or allergic reaction to exosomes","40 Years",{"count":427,"type":22},15,[57,58],"Intradermal injection of exosomes in treatment of male androgenetic alopecia, clinically and using a immunohistochemical marker",[29],[29],"2025-08-01",{"date":434,"type":37},"2025-08-08",{"date":436,"type":22},"2025-08-30",{"date":187,"type":22},{"name":439,"class":44},"Ain Shams University",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":114,"minAge":18,"maxAge":115,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":45},"100586547","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-ckd-843-in-male-patients-with-androgenetic-alopecia-100586547","NCT06916793","A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia","Key Inclusion Criteria:\n\n* Male of age 18-50 years\n* Clinical Diagnosis of Androgenetic Alopecia\n* Written informed consent\n\nKey Exclusion Criteria:\n\n* Other types of Alopecia or other diseases that can cause hair loss\n* Clinically significant scalp disease such as seborrheic dermatitis or psoriasis\n* Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator\n* Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose",{"count":448,"type":22},288,[89],"This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia",[29],"2025-04-01",{"date":454,"type":37},"2025-04-08",{"date":456,"type":22},"2025-04-30",{"date":458,"type":22},"2027-09-17",{"name":460,"class":77},"Chong Kun Dang Pharmaceutical",{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":114,"minAge":18,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":474,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":299},"100580757","six-month-single-blind-placebo-controlled-study-of-a-dietary-supplement-supplement-on-hair-growth-in-45-volunteers-100580757","NCT06841458","Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers","Instrumental, Single-Blind, Placebo-Controlled Study Evaluating the Efficacy of a Dietary Supplement on Hair Growth Over 6 Months in 45 Volunteers","Inclusion Criteria:\n\n* Written consent for LOPD compliance.\n* Written informed consent for study DC.506.36.117.\n* Gender: Male.\n* Age: Between 18 and 45 years.\n* Diagnosis of alopecia with low hair density, classified as mild to moderate (stages II, III, and IV on the Hamilton-Norwood scale).\n\nWillingness to have a 1-2 cm² area shaved throughout the study period.\n\n* Last participation in a clinical study on hair health must have ended at least six months before the start of this study.\n* 30-day washout period without specific hair treatments (using a neutral shampoo).\n* No use of any other topical or oral hair treatments in the target area during the study period; if necessary, consultation with the principal investigator is required to evaluate continued study participation.\n\nExclusion Criteria:\n\n* Individuals with gastrointestinal diseases (e.g., diabetes, gastritis, Crohn's disease, celiac disease, ulcers, intolerances, etc.).\n* Individuals with other physiological disorders (e.g., diabetes, hypertension, dyslipidemia) and\u002For gallstones.\n* Individuals undergoing medical treatment in the weeks prior to the study that may interfere with study assessments (as determined by the investigator), particularly those who are currently taking or have taken 5α-reductase inhibitors (Finasteride, Dutasteride, Minoxidil, etc.) within the last three months.\n\nIndividuals who have undergone hair restoration treatments at any point in their lives, including hair transplants, mesotherapy, or platelet-rich plasma (PRP) therapy.\n\n* Individuals following an atypical diet or planning to change their dietary routine during the study period.\n* Individuals enrolled in another clinical study with similar characteristics (as determined by the investigator) during the study period.\n* Individuals who are unable to fully understand the informed consent document or adhere to the study protocol.","45 Years",{"count":470,"type":22},45,[25],"This clinical study is designed to evaluate the efficacy and safety of a dietary supplement CL-P24113a for the management of androgenetic alopecia (AGA) in male subjects aged 18 to 45 years who suffer from alopecia with low hair density, classified as mild to moderate (Hamilton-Norwood stages II, III, and IV). The product is a formulation based on a blend of botanical ingredients and other well-established compounds, including Pumpkin Seed Oil (Curcubita pepo), Saw Palmetto Oil (Serenoa repens), L-Cystine, Prunus africana Bark Extract (Pygeum africanum), Horsetail Extract (Equisetum arvense), Olive Leaf Extract, among other excipients. These components have a well-documented history of safe use in both topical and oral applications with supporting safety information from international bodies such as EFSA. In this instrumental, single-blind, placebo-controlled study, 45 volunteers will be divided into two groups, with 30 subjects receiving the supplement and 15 subjects receiving a placebo. All participants will ingest one capsule per day, preferably in the morning with a glass of water, over a 6-month treatment period. Prior to study initiation, subjects must complete a 30-day washout period using a neutral shampoo and agree not to apply any other topical or oral hair treatments in the target area throughout the study. The study will evaluate efficacy through both instrumental and subjective assessments. Instrumental evaluations will be conducted at 3 and 6 months using the TrichoScan HD Professional 4.0 system to measure hair growth parameters such as total hair count, hair density per cm², proportion of hairs, terminal hair count and density, proportion of terminal hairs, as well as the percentages of anagen and telogen hairs. Additionally, measurements of hair thickness including hair mass per cm², median and mean hair thickness in micrometers, overall scalp hair density, and median hair length will be recorded. Subjective evaluations will be performed via questionnaires administered at 1.5, 3, 4.5, and 6 months to capture participants' perceptions regarding hair growth and hair loss. The study is overseen by Principal Investigator at Dermaclaim Lab S.L. Regulatory compliance will be ensured by obtaining written informed consent for both study participation and data protection, and all subjects will be thoroughly briefed on study requirements and potential risks. This study aims to provide robust clinical evidence on the effectiveness of the oral supplement in promoting hair growth and reducing hair loss in men affected by androgenetic alopecia, potentially offering a safe and well-tolerated alternative to existing hair loss therapies while ensuring continuous monitoring for any adverse events throughout the treatment period.",[29],[475,29,476,477,478,63],"MAGA","Natural supplement","Saw Palmetto","Cucurbita Pepo","2025-02-21",{"date":317,"type":37},{"date":482,"type":37},"2024-10-07",{"date":484,"type":22},"2025-06-01",{"name":105,"class":77},{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":114,"minAge":493,"maxAge":115,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":45},"100579569","phase-2-various-procedural-treatment-options-for-androgenetic-alopecia-100579569","NCT06826001","Various Procedural Treatment Options for Androgenetic Alopecia","COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA","Inclusion Criteria:\n\n* Age: 20-50 years\n* Gender: Male\n* ANDROGENETIC ALOPECIA with AGA stage 2-6 Norwood-Hamilton -classification\n* Patients not taking any treatment in last 1 month\n\nExclusion Criteria:\n\n* Abrasion or abnormalities to the scalp\n* Hair transplant\n* Hypersensitivity\n* Recent history of local infections of the head\n* History of relevant significant disease active seborrheic dermatitis\n* Concurrent use of :\n* corticosteroids\n* anabolic steroids or over-the-counter 'hair restorers'\n* use of drugs with anti-androgenic properties within 6 months light or laser treatment of the scalp within the last 3 months.","20 Years",{"count":357,"type":22},[58],"Androgenetic alopecia (AGA)is the most common form of alopecia. It predominantly affects males, but there has been a significant surge in female preponderance too, over the last decade Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years so in this study we are going to compare efficacy of topical minoxidil versus topical finasteride in treatment of androgenetic alopecia",[29],[362,499,125,500],"finasteride","hairloss","2025-02-07",{"date":503,"type":37},"2025-02-13",{"date":505,"type":22},"2025-02",{"date":507,"type":22},"2025-07",{"name":509,"class":510},"Sheikh Zayed Medical College","OTHER_GOV",{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":4},"100554656","phase-3-clinical-study-of-da-002-and-da-005-as-a-treatment-for-hair-loss-100554656","NCT06501924","Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with androgenetic alopecia\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-002 or DA-005\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits",{"count":518,"type":22},516,[89],"The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).",[29,92,206],"2024-12-17",{"date":524,"type":37},"2024-12-19",{"date":526,"type":22},"2025-01-15",{"date":528,"type":22},"2025-12-12",{"name":215,"class":77},{"id":531,"slug":532,"hasResults":11,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":16,"sex":114,"minAge":18,"maxAge":537,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":540,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":4},"100561485","benefits-of-a-cosmetic-anti-hair-loss-in-males-with-hair-loss-100561485","NCT06590779","Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss","Evaluation of the Benefits of a Cosmetic Anti-hair Loss Lotion Applied in Combination With Finasteride in Male Subjects With Hair Loss: Investigator-blinded, Randomized, Multi-center Study Performed Under Dermatological Control","Inclusion Criteria:\n\n* Male subject aged 18-41 years old with skin type I to IV according to the Fitzpatrick scale;\n* Affected by androgenetic alopecia with hair loss evaluated grade IIA to IV the modified Norwood-Hamilton scale;\n* Subject with chestnut brown, dark or black hair;\n* Subject with hair length ≥ 3 cm on the vertex and agreeing to keep this minimum length for the duration of the study;\n* Subject agreeing to have a shaved zone of 1.5 cm² on scalp area;\n* Subject accepting not to dye, bleach his hair or to do a permanent wave during the whole study duration;\n* Subject accepting to use condoms if her partner is pregnant.\n\nExclusion Criteria:\n\n* Female subject;\n* Subject presenting a life-threatening endocrine disease, neoplasia or other serious diseases;\n* Subjects suffering from chemo-induced alopecia (poisoning, medicines), or resulting from a chronic disease (genetic, endocrine, immunological, deficiencies), seasonal hair loss;\n* Subject having any other concomitant dermatological affection of the scalp (psoriasis, seborrheic dermatitis, eczema, other alopecia than androgenetic);\n* Subject suffering from a recurrent, acute, non-stabilized or evolving disease judged by the investigator able to interfere with the study needs and hair growth;\n* Subject having had surgical intervention for capillary correction (e.g., hair transplant) or intending to have recourse to this surgery during the entire study period;\n* Subject presenting a hypersensitivity to any of the components of the finasteride medication or to any 5-alpha-reductase inhibitor;\n* Subject that has applied or taken prior to the start of the study (screening) interfering drugs or products\n* Subject taking any other medical treatment (topic or per os) likely to interfere on hair growth or hair loss within 6 months prior to the screening visit;\n* Subject following a long period (\\>30 days) treatment of anti-inflammatory within 4 months prior to the start of the study (screening visit);\n* Subject taking topic cosmetic treatment or per os nutritional supplement likely to interfere on hair growth or hair loss during the last 3 months prior to the screening visit;\n* Subject having a topical or oral route treatment of the scalp (anti-seborrheic, anti-dandruff, daily friction) within 2 weeks prior to the screening visit;\n* Subject who has been exposed within one month prior to the screening visit in an intense or excessive manner to sun (natural or artificial) or during the study;\n* Subject having a wig or hair extension;\n* Protected subject as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or subject to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person subject to a legal protection measure or unable to express his\u002Fher consent;\n* Subject unable to communicate or cooperate with the Investigator due to poor mental development, language problems or impaired cerebral function;\n* Subject currently participating in another clinical study or being in an exclusion period of another clinical study;","41 Years",{"count":539,"type":22},140,[25],"Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. AGA is a polygenetic condition with varying severity, age of onset, and scalp location of hair loss. In men, hair loss typically involves the temporal and vertex region while sparing the occipital region: the characteristic \"horseshoe\" pattern. Incidence and prevalence of AGA depend on age and race.\n\nVichy has developed a new cosmetic anti hair loss lotion with the aim of acting on androgenic alopecia. The aim is to improve the efficacy on hair loss of the association of the lotion with finasteride versus finasteride alone.\n\nThe primary objective of this investigator-blinded, randomized multi-center study is to quantitatively evaluate, using the phototrichogram method, the efficacy of a lotion associated with finasteride versus finasteride alone on hair growth parameters in male subjects with androgenetic alopecia.",[29],"2024-09-10",{"date":545,"type":37},"2024-09-19",{"date":547,"type":22},"2024-11-02",{"date":549,"type":22},"2026-05-02",{"name":551,"class":77},"Cosmetique Active International",{"id":553,"slug":554,"hasResults":11,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":11,"sex":114,"minAge":18,"maxAge":172,"enrollmentInfo":559,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":45},"100559010","efficacy-of-stromal-vascular-fraction-versus-platelet-rich-plasma-in-treatment-of-androgenitic-alopecia-100559010","NCT06558565","Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia","Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia:Randomized Clinical Trial","Inclusion Criteria:\n\n* 18 years or older.\n* Hamilton score I to VI in male patients.\n\nExclusion Criteria:\n\n* Patients with active infection, malignancy, autoimmune disease, and on current anticoagulant therapy.\n* Patient on chemotherapy during the last 5 years.\n* patients on topical or systemic treatment of AGA",{"count":560,"type":22},20,[25],"The goal of this randomized controlled clinical trial is to test the efficacy \\& safety of stromal vascular fraction in treatment of AGA \\& compare it to PRP The main questions it aims to answer are:\n\n* efficacy \\& safety of SVF for treatment of AGA patients\n* comparing it to PRP in treatment of AGA Participants will receive a single session of SVF in one half of the scalp \\& a single session of PRP in the other half.",[29],[565],"stromal vascular fraction - PRP- androgenetic alopecia","2024-08-14",{"date":568,"type":37},"2024-08-16",{"date":570,"type":22},"2024-08-30",{"date":452,"type":22},{"name":134,"class":44},{"id":574,"slug":575,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":585,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":45},"100553165","phase-1-efficacy-and-safety-of-age-zero-exosomes-to-treat-men-and-women-with-androgenetic-alopecia-100553165","NCT06482541","Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia","1-Year Double-Blind Placebo-Controlled Study To EVALUATE THE EFFECT OF AGE ZERO™ EXOSOMES ON HAIR REGROWTH IN HEALTHY MEN AND WOMEN WITH ANDROGENETIC ALOPECIA","Inclusion Criteria:\n\n* Participant is experiencing hair loss and is diagnosed with Androgenetic Alopecia.\n\nExclusion Criteria:\n\n* Patients cannot have taken any medications, therapies, or treatment modalities of any kind to treat hair loss in the last six months.\n* Patients cannot have open wounds, eczema, or psoriatic plaques on the treatment area of the scalp.\n* Patients who are undergoing or have undergone chemotherapy and or radiation therapy within the past 6 months\n* Patients with a history of an autoimmune bullous disorder (having auto-antibodies to Dsg-1 or Dsg-3)\n* Patients who are currently immunocompromised or have a low white count making patients prone to infections.",{"count":581,"type":22},100,[57],"The purpose of this study is to determine whether Wharton's Jelly mesenchymal stem cell-derived exosome microneedling on the scalp is an effective treatment for Androgenetic Alopecia (pattern hair loss).",[29],[586,29],"exosomes","2024-07-13",{"date":589,"type":37},"2024-07-16",{"date":591,"type":22},"2024-07",{"date":593,"type":22},"2025-08",{"name":595,"class":44},"Levit Dermatology"]